Company Filing History:
1 out of 30 
1 out of 340 
1 out of 1,248 
Years Active: 1980-2008
Title: Innovations of Hans Paulsen in Tumor Vaccines
Introduction
Hans Paulsen is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of medical research, particularly in the development of tumor vaccines. With a total of four patents to his name, his work focuses on innovative solutions for combating cancer.
Latest Patents
One of Hans Paulsen's latest patents involves tumor vaccines for MUC1-positive carcinomas. This invention presents a tumor vaccine containing synthetic peptides that comprise sequences of the human epithelial mucin MUC1. The vaccine includes the immunodominant region PDTRPAP, which is glycosylated at the threonine. The preferred glycosylation of this region is an O-glycosidically linked N-acetylgalactosamine (GalNAc) or short-chained oligosaccharides. This invention can be utilized for all MUC1-positive carcinomas. Another patent describes chemical compounds and amino acids attached to glycosides, detailing compounds with specific formulas and their potential use as antigens or immunoadsorbents.
Career Highlights
Throughout his career, Hans Paulsen has worked with prominent organizations such as the Max Delbrück Center for Molecular Medicine and Behringwerke Aktiengesellschaft. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.
Collaborations
Hans Paulsen has collaborated with various professionals in his field, including his coworker Peter Stadler. These collaborations have played a crucial role in enhancing the quality and impact of his research.
Conclusion
Hans Paulsen's work in developing tumor vaccines and his innovative approach to medical research highlight his importance as an inventor. His contributions continue to pave the way for advancements in cancer treatment.